Advances in Peptide Stability and Gut Absorption: Overcoming the Oral Bioavailability Challenge

Oral delivery of peptide therapeutics has long been constrained by two fundamental barriers: enzymatic degradation in the gastrointestinal tract and poor transepithelial absorption. Recent formulation advances are beginning to address both problems, with implications for the broader pipeline of peptide-based drugs under development.

The Enzymatic Barrier

Peptides are hydrolysed rapidly by proteases in the stomach and small intestine. Pepsin, trypsin, and chymotrypsin cleave peptide bonds before the molecule can reach the intestinal epithelium intact. For GLP-1 receptor agonists, which are peptides of roughly 30–40 amino acids, this degradation limits the fraction of an oral dose that reaches systemic circulation to well below 1% in unmodified formulations.

Strategies to circumvent enzymatic breakdown include co-formulation with protease inhibitors, encapsulation in enteric coatings that resist gastric acid, and structural modifications such as amino acid substitution or lipidation that reduce susceptibility to cleavage. Each approach carries trade-offs in manufacturing complexity and cost.

Absorption Enhancement Technologies

Even when a peptide survives transit intact, the intestinal epithelium presents a physical barrier. Tight junctions between enterocytes limit paracellular transport, and the hydrophilic, high-molecular-weight character of peptides restricts transcellular diffusion. Absorption enhancers that transiently open tight junctions — including salcaprozate sodium (SNAC) and related medium-chain fatty acid derivatives — have emerged as the leading approach for oral peptide formulations.

SNAC works by creating a local concentration gradient at the gastric mucosa, facilitating passive diffusion of the co-administered peptide. This mechanism was central to the development of oral semaglutide, and the same class of enhancers is now being evaluated across multiple oral incretin programs.

Implications for the Pipeline

As absorption enhancer platforms mature, they can be applied to peptide candidates beyond GLP-1 agonists. Oral formulations of amylin analogs, dual incretins, and peptide hormone conjugates are all under investigation. ClinicalTrials.gov registrations show a steady increase in oral peptide trials across metabolic, endocrine, and gastrointestinal indications.

For researchers, the practical question is whether improved bioavailability will enable new experimental designs — fixed-dose combinations, population-level adherence studies, and chronic dosing models — that were previously limited by injectable-only delivery.

For educational purposes only. This content is informational and reflects publicly reported research developments. It is not medical advice and makes no therapeutic claims. Products referenced are for research use only. Consult a qualified healthcare professional for any medical question.